Scottish Medicines Consortium seeks role in new UK value-based pricing system
This article was originally published in Scrip
The Scottish Medicines Consortium (SMC), the health technology assessment body for Scotland, could have a role to play in value based pricing, which the UK coalition government says will replace the current Pharmaceutical Pricing and Reimbursement Scheme (PPRS) in 2014.
You may also be interested in...
While information sharing is key to cross-country collaborations on access to medicines and can lead to major benefits, it is hard to sell to political leaders and the media, says a report from the World Health Organization’s regional office for Europe.
The European Commission says it will publish its review of the EU orphan drug legislation in the coming days.
The UK has formally withdrawn its ratification of the Unified Patent Court Agreement, adding to the uncertainty over its future.